FDA Drug recall D-0076-2025
Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 277…
- FDA Drug
- Class II
- completed
- Published 2024-12-11
On 2024-12-11 the FDA classified a Class II recall of Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 277… by Accord Healthcare, citing subpotent drug.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0076-2025 |
| Classification | Class II |
| Status | completed |
| Initiated | 2024-11-08 |
| Published | 2024-12-11 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Accord Healthcare |
| Distribution | US |
Product
Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-449-17
Reason
Subpotent drug
Identifiers
| ndc | 16729-458-15 |
|---|---|
| ndc | 16729-458-17 |
| ndc | 16729-447-15 |
| ndc | 16729-447-17 |
| ndc | 16729-448-15 |
| ndc | 16729-448-17 |
| ndc | 16729-449-15 |
| ndc | 16729-449-17 |
| ndc | 16729-451-15 |
| ndc | 16729-451-17 |
| ndc | 16729-450-15 |
| ndc | 16729-450-17 |
| ndc | 16729-452-15 |
| ndc | 16729-452-17 |
| ndc | 16729-453-15 |
| ndc | 16729-453-17 |
| ndc | 16729-454-15 |
| ndc | 16729-454-17 |
| ndc | 16729-455-15 |
| ndc | 16729-455-17 |
| ndc | 16729-456-15 |
| ndc | 16729-456-17 |
| ndc | 16729-457-15 |
| ndc | 16729-457-17 |
| code_info | Lot #: D2300191, Exp 12/31/2025 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: completed.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0076-2025%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.